Harbour BioMed to Showcase HBM4003 and Tislelizumab Trial Results at ESMO 2025
Harbour BioMed to Present Important Clinical Trial Data at ESMO 2025
Harbour BioMed, a leading biopharmaceutical company, has announced it will present Phase II clinical trial results for its innovative anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for treating microsatellite stable (MSS) metastatic colorectal cancer. This significant announcement came ahead of the ESMO Congress 2025, scheduled for October 17-21 in Berlin, Germany.
The Challenge of MSS Metastatic Colorectal Cancer
MSS metastatic colorectal cancer is particularly hard to treat, as patients often show limited responses to existing immune checkpoint inhibitors. Current treatments have faced challenges, leading researchers to explore new combinations of therapies. In preclinical studies, combining CTLA-4 blockade with PD-(L)1 inhibition has shown promise, providing a strong rationale for the Phase II trial.
The multicenter, open-label study, registered under NCT05167071, involved patients who were heavily pre-treated and had non-liver metastatic MSS colorectal cancer. The preliminary data regarding efficacy and safety is expected to be unveiled during a poster session at the congress.
HBM4003: A Breakthrough in Antibody Therapy
HBM4003, known as Porustobart, is a next-generation human antibody that specifically targets CTLA-4. Uniquely developed using Harbour Mice® technology, this antibody exhibits distinct advantages over traditional CTLA-4 therapies. It shows enhanced Treg cell depletion and optimized pharmacokinetics, which may result in improved safety for patients. Moreover, its ability to boost antibody-dependent cellular cytotoxicity (ADCC) allows for more effective targeting of tumor cells.
With HBM4003 entering clinical trials as the first fully human heavy-chain-only antibody, Harbour BioMed hopes to offer new hope for patients who have limited treatment options.
Presentation Details
The details of the presentation at ESMO are as follows:
- - Title: Efficacy and Safety of HBM4003, an anti-CTLA-4 Antibody, Combined with Tislelizumab in MSS Metastatic Colorectal Cancer: A Multicenter, Phase II Study
- - Presentation Number: 807P
- - Speaker: Frank Zheng
The accepted abstracts from the conference will also be published on the ESMO website, showcasing the latest developments in cancer therapeutics.
About Harbour BioMed
Harbour BioMed is committed to advancing cancer treatments through the development of novel antibody therapeutics. The company utilizes its proprietary Harbour Mice® technology to generate fully human monoclonal antibodies efficiently. With a strong pipeline focused on immunology and oncology, Harbour BioMed strives to tackle various forms of solid tumors and improve patient outcomes worldwide. By integrating innovative technologies and strategic partnerships, Harbour BioMed continues to remain at the forefront of biopharmaceutical advancements.
For further information about Harbour BioMed and its groundbreaking therapies, please visit www.harbourbiomed.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.